Sanofi-aventis Unveils Lantus Study Results
The study showed long term safety of Lantus as compared to NPH
French pharmaceutical company Sanofi-aventis has unveiled the results of the five-year study of Lantus (insulin glargine injection) versus NPH insulin, on progression of retinopathy in patients with type 2 diabetes. The results showed similar effects on retinopathy and overall safety in the two treatment groups, said the company.
In the study of patients with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment. This indicates that Lantus does not have mitogenic effects different from the human NPH insulin within the eye.
The open-label study was specifically designed to characterize the retinal safety profile of Lantus versus NPH in 1024 patients (Lantus once daily: 515 patients and NPH twice daily: 509 patients).
Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, said: This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin. This study demonstrated no evidence of a greater risk of progression of retinopathy with insulin glargine.
Latest News
Related News
Production & Manufacturing> Manufacturing
Related Dates
2009> July
Related Industries
Pharmaceuticals and Healthcare> Services> Outsourced Services> Contract Manufacturers
Pharmaceuticals and Healthcare> Drug Manufacturing
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500

Comments may be moderated for spam, obscenities or defamation.